Dysregulation of immune checkpoint pathways, like the TIGIT/CD226 axis, has been implicated in complications such as recurrent implantation failure and preeclampsia, suggesting a role for checkpoint modulation in therapeutic strategies [67,70]. Here, TIGIT is linked to preeclampsia.